6th International Workshop on Clinical Pharmacology of HIV Therapy

Bibliography

• MOLTO J, VALLE M, BLANCO A et al.: Exposure to lopinavir (LPV) among HIV/HCV co-infected patients without liver function impairment. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 36.
   Google Scholar
• COOPER C, VAN HEESWIJK RP, BILODEAU M et al.: The pharmacokinetics (PK) of single-dose and steady-state tipranavir/ritonavir (TPV/r) 500/200 mg in subjects with mild or moderate hepatic impairment. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 45.
   Google Scholar
• SEMINARI E, GENTILINI G, DE BONA A et al.: Liver cirrhosis but not chronic hepatitis is associated to higher amprenavir plasma levels in patients treated with fosamprenavir/ritonavir. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 66.
   Google Scholar
• GRANGE S, SCHUTZ M, SCHMITT C, RIEK M, GAUDEUL-EHRHART E: Unexpected hepatotoxicity observed in a healthy volunteer study on the effects of multiple dose rifampicin on the steady-state pharmacokinetics of ritonavir-boosted saquinavir and vice versa. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 35.
   Google Scholar
• DICKINSON L, BACK DJ, CHANDLER B et al.: The impact of gender on saquinavir hard-gel/ritonavir (1000/100 mg BID) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 9.
   Google Scholar
• ROBERTSON S, FALLOON J, FORMENTINI E, ALFARO R, PENZAK S: Lack of sex-related differences in saquinavir pharmacokinetics in an HIV seronegative cohort. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 50.
   Google Scholar
• CAPPARELLI E, AWEEKA F, BEST B et al.: Effect of pregnancy on nevirapine pharmacokinetics during chronic therapy. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 38.
   Google Scholar
• ZILLY M, WINZER R, NOLTE C et al.: Double PI boosting with atazanavir and fos-amprenavir: favourable pharmacokinetics. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 93.
   Google Scholar
• LANGMANN P, ZILLY M, WINZER R et al.: Efficacy and safety of ATV in combination with LPV/r. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 56.
   Google Scholar
• KUROWSKI M, MOLTO J, BRESKE A et al.: Atazanavir (ATV) enhances trough concentrations of nelfinavir (NFV) and its M8 metabolite in a treatment regimen without ritonavir (RTV). 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 90.
   Google Scholar
• GONZALEZ DE REQUENA D, BONORA S, CAVECHIA I et al.: Atazanavir Ctrough is associated with efficacy and safety at 24 weeks: Definition of therapeutic range. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 60.
   Google Scholar
• BONORA S, GONZALEZ DE REQUENA D, AGUILAR MARUCCO D et al.: Pharmacokinetic (PK) and pharmacodynamic (PD) determinants of early virological response to enfuvirtide-based regimens. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 71.
   Google Scholar
• HARRIS M, JOY R, LARSEN G et al.: Enfuvirtide (T20) plasma levels using a novel needle-free gas-powered injection system (Biojector) for subcutaneous administration of T20 in treatment-experienced HIV+ patients. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 48.
   Google Scholar
• COLOMBO S, SORANZO N, ROTGER M et al.: Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the intracellular concentrations of nelfinavir. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 96.
   Google Scholar
• KUROWSKI M, WALLI R, BRESKE A et al.: Coadministration of tenofovir 300 mg/day with fosamprenavir/ritonavir 1400/100 mg/day or 1400/200 mg/day does not affect amprenavir pharmacokinetics. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 10.
   Google Scholar
• PEYTAVIN G, MARCELIN AG, ROUAULT A et al.: Plasma concentrations of amprenavir, ritonavir and tenofovir in HIV-infected patients treated with fosamprenavir/ritonavir (700/100 mg BID) and tenofovir (300 mg/day) containing regimen. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. (April 28 – 30, 2005) Abstr. 32.
   Google Scholar
• VINCENT I, BARRAIL A, PIKETTY C et al.: Pharmacokinetic parameters of tenofovir when combined with atazanavir/ritonavir in HIV infected patients with multiple treatment failures: A substudy of Puzzle 2-ANRS 107 Trial. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 55.
   Google Scholar
• AGARWALA S, ELEY T, VILLEGAS C et al.: Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 16.
   Google Scholar
• PRUVOST A, NEGREDO E, BENECH H, GRASSI J, CLOTET B: Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs: analysis in HIV-infected patients. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 20.
   Google Scholar
• SEKAR V, HOETELMANS RM, DE MAREZ T et al.: Pharmacokinetics of TMC114: Effect of omeprazole and ranitidine. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr.17.
   Google Scholar
• AGARWALA S, ELEY T, CHILD M et al.: Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 11.
   Google Scholar
• SHELTON MJ, FORD SL, WIRE MB et al.: Coadministration of esomeprazole (ESO) with fosamprenavir (fAPV) has no impact on steady-state plasma amprenavir (APV) pharmacokinetics (APV10031). 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 24.
   Google Scholar
• ABEL S, RUSSELL D, RIDGWAY C, MUIRHEAD G: Overview of the drug-drug interaction data for maraviroc (UK-427,857). 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 76.
   Google Scholar
• ADKISON K, LOU Y, FANG L et al.: Pharmacokinetic/pharmacodynamic (PK/PD) relationships of the novel CCR5 antagonist, 873140, during a 10-day monotherapy study in HIV-infected subjects. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 77.
   Google Scholar
• JOHNSON B, SONG I, ADKISON K et al.: 873140, a novel CCR5 receptor antagonist, does not significantly interact with major drug metabolizing enzymes. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 75.
   Google Scholar
• SANSONE A, GUILLAUME M, KRAAN M et al.: Pharmacokinetics of SCH-417690 administered alone and in combination with tenofovir. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 85.
   Google Scholar
• SANSONE A, GUILLAUME M, KRAAN M et al.: The pharmacokinetics of SCH-417690 when administered alone and in combination with lamivudine/zidovudine. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 84.
   Google Scholar
• SANSONE A, SEIBERLING M, KRAAN M, KEUNG A, MARTINHO M: Similar increase in SCH-417690 plasma exposure with coadministration of varying doses of ritonavir in healthy volunteers. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 78.
   Google Scholar
• SANSONE A, SALTZMAN M, ROSENBERG M et al.: Pharmacokinetics of SCH-417690 administered alone or in combination with ritonavir or lopinavir/ritonavir. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 83.
   Google Scholar
• SANSONE A, SALTZMAN M, ROSENBERG M et al.: Pharmacokinetics of SCH-417690 administered alone or in combination with ritonavir and efavirenz in healthy volunteers. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 79.
   Google Scholar
• HOETELMANS RM, KESTENS D, MARIEN K et al.: Effect of food and multiple dose pharmacokinetics of TMC278 as an oral tablet formulation. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 80.
   Google Scholar
• HOETELMANS RM, KESTENS D, STEVENS M et al.: Pharmacokinetic interaction between the novel non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 and tenofovir disoproxil fumarate (TDF) in healthy volunteers. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 18.
   Google Scholar
• SCHOLLER M, HOETELMANS RM, BOLLEN S et al.: No significant interaction between TMC125 and didanosine (ddI) in healthy volunteers. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 29.
   Google Scholar
• SCHOLLER M, HOETELMANS RM, BEETS G et al.: Substantial improvement of oral bioavailability of TMC 125 using new tablet formulations in healthy volunteers. 6th International Workshop on the Clinical Pharmacology of HIV Therapy. Quebec City, Canada (April 28 – 30, 2005) Abstr. 82.
   Google Scholar